FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2952212829> ?p ?o ?g. }

• W2952212829 abstract "Background The abatacept global post-marketing epidemiology programme consists of observational studies based on biologic disease registries and healthcare claims databases to assess infection and malignancy risks associated with abatacept treatment, as used in routine clinical practice. Objectives To evaluate the risk of infection in patients with RA treated with abatacept versus conventional synthetic (cs)DMARDs and other biologic (b) or targeted synthetic (ts)DMARDs. Methods Data were analysed from five cohorts: two biologic registries (the Anti-Rheumatic Therapy in Sweden register and the Rheumatoid Arthritis Observation of Biologic Therapy German registry), a disease registry (FORWARD, The National Databank for Rheumatic Diseases in the USA) and two healthcare claims databases (the population-based British Columbia Canadian RA Cohort and the US Optum Research Database). Crude incidence rates (per 1000 patient-years of exposure) with 95% CIs were calculated for hospitalised infections and opportunistic infections. Adjusted risk ratios (RRs) with 95% CIs were estimated using multivariate models adjusting for demographics, co-morbidities and other potential cofounders within each database and were subsequently pooled using a random effects model for meta-analyses.1 Results From all cohorts, patients treated with abatacept (∼6400), csDMARDs (∼137K) and other b/tsDMARDs (∼54K) were followed up for a mean of 2.3–3.7, 2.2–6.2 and 2.3–4.7 years, respectively. Patients were mainly female (71–86%), with a mean age ranging from 49–63 years, and 3–18% had a history of prior severe infections across treatment groups/cohorts. A greater number of abatacept-treated patients had a history of ≥2 prior biologics (44–85% vs csDMARDs, 11% [FORWARD] and other b/tsDMARDs, 0–19%). In abatacept-treated patients, incidence rates for hospitalised infections ranged from 16–56 and opportunistic infections from 0.4–7.8 (Table). Adjusted RRs (95% CIs) for abatacept vs csDMARDs (range: 0.3 [0.2, 0.7] to 2.2 [1.3, 3.7]; pooled estimate: 1.2 [0.6, 2.2]) and abatacept vs other b/tsDMARDs (range: 0.5 [0.3, 0.8] to 1.3 [0.8, 2.1]; pooled estimate: 0.9 [0.6, 1.3]) showed no increased risk in hospitalised infections. Conclusion In this large, international post-marketing epidemiology programme, pre-specified infection risks were more frequent with abatacept than csDMARDs and b/tsDMARDs in some, but not all, cohorts. Increased risks for individual outcomes/cohorts may be attributed to prior biologic exposure, study design and practice pattern differences. These data are consistent with the current safety profile of abatacept. References [1] DerSimonian R, Laird N. Control Clin Trials 1986;7:177–188. Acknowledgement Professional Medical writing: Rachel Rankin, PhD, Caudex; funding: Bristol-Myers Squibb Disclosure of Interests Teresa Simon Employee of: Bristol-Myers Squibb, Samy Suissa Grant/research support from: Advisory board meetings, or as speaker, or received research grants from AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Novartis, Speakers bureau: Advisory board meetings, or as speaker, or received research grants from AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Novartis, Mary Lou Skovron Shareholder of: Bristol-Myers Squibb, Consultant for: Bristol-Myers Squibb, Thomas Frisell: None declared, Johan Askling Grant/research support from: Karolinska Institutet (JA) has or has had research agreements with the following pharmaceutical companies, mainly in the context of the ATRIS national safety monitoring programme for rheumatology biologicals: Abbvie, BMS, MSD, Eli Lilly, Pfizer, Roche, Samsung Bioepis, and UCB., Consultant for: Karolinska Institutet has received remuneration for JA participating in ad boards arranged by Lilly, Novartis, and Pfizer., Kaleb Michaud Grant/research support from: Research grant funding in the last 2 years from Rheumatology Research Foundation and Pfizer, Sofia Pedro Employee of: FORWARD, The National Data Bank of Rheumatic Diseases, Anja Strangfeld Speakers bureau: Speakers fees from Bristol-Myers Squibb, MSD, Pfizer, Roche, Maarten Boers Consultant for: Bristol-Myers Squibb, Teva, Novartis, Pfizer, GlaxoSmithKline, Diane Lacaille Grant/research support from: Bristol-Myers Squibb and Eli Lilly Canada, Marc Hochberg Shareholder of: BriOri Biotech, Theralogix LLC., Consultant for: Bristol Myers Squibb, Eli Lilly, EMD Serono, Novartis Pharma AG, Pfizer Inc., Samumed LLC, Symic Bio Inc., Theralogix LLC, TissueGene Inc., TLC Biopharmaceuticals, Inc., Zynerba, Galapagos, IQVIA, Hoffman LaRoche., Veena Hoffman Shareholder of: UnitedHealth Group, Inc (parent company of Optum), Employee of: Optum, Andres Gomez Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb" @default.
• W2952212829 created "2019-06-27" @default.
• W2952212829 creator A5005535362 @default.
• W2952212829 creator A5007668495 @default.
• W2952212829 creator A5008217187 @default.
• W2952212829 creator A5025815003 @default.
• W2952212829 creator A5026165132 @default.
• W2952212829 creator A5031834210 @default.
• W2952212829 creator A5044067217 @default.
• W2952212829 creator A5044831604 @default.
• W2952212829 creator A5046535398 @default.
• W2952212829 creator A5047429949 @default.
• W2952212829 creator A5078154358 @default.
• W2952212829 creator A5082099394 @default.
• W2952212829 creator A5086239129 @default.
• W2952212829 date "2019-06-01" @default.
• W2952212829 modified "2023-10-11" @default.
• W2952212829 title "FRI0118 INFECTION OUTCOMES IN PATIENTS WITH RA TREATED WITH ABATACEPT AND OTHER DMARDS: RESULTS FROM A 10-YEAR INTERNATIONAL POST-APPROVAL STUDY" @default.
• W2952212829 doi "https://doi.org/10.1136/annrheumdis-2019-eular.1725" @default.
• W2952212829 hasPublicationYear "2019" @default.
• W2952212829 type Work @default.
• W2952212829 sameAs 2952212829 @default.
• W2952212829 citedByCount "2" @default.
• W2952212829 countsByYear W29522128292021 @default.
• W2952212829 countsByYear W29522128292023 @default.
• W2952212829 crossrefType "proceedings-article" @default.
• W2952212829 hasAuthorship W2952212829A5005535362 @default.
• W2952212829 hasAuthorship W2952212829A5007668495 @default.
• W2952212829 hasAuthorship W2952212829A5008217187 @default.
• W2952212829 hasAuthorship W2952212829A5025815003 @default.
• W2952212829 hasAuthorship W2952212829A5026165132 @default.
• W2952212829 hasAuthorship W2952212829A5031834210 @default.
• W2952212829 hasAuthorship W2952212829A5044067217 @default.
• W2952212829 hasAuthorship W2952212829A5044831604 @default.
• W2952212829 hasAuthorship W2952212829A5046535398 @default.
• W2952212829 hasAuthorship W2952212829A5047429949 @default.
• W2952212829 hasAuthorship W2952212829A5078154358 @default.
• W2952212829 hasAuthorship W2952212829A5082099394 @default.
• W2952212829 hasAuthorship W2952212829A5086239129 @default.
• W2952212829 hasBestOaLocation W29522128291 @default.
• W2952212829 hasConcept C107130276 @default.
• W2952212829 hasConcept C120665830 @default.
• W2952212829 hasConcept C121332964 @default.
• W2952212829 hasConcept C126322002 @default.
• W2952212829 hasConcept C1862650 @default.
• W2952212829 hasConcept C198451711 @default.
• W2952212829 hasConcept C23276603 @default.
• W2952212829 hasConcept C2426938 @default.
• W2952212829 hasConcept C2777575956 @default.
• W2952212829 hasConcept C2779338263 @default.
• W2952212829 hasConcept C2779605438 @default.
• W2952212829 hasConcept C2780653079 @default.
• W2952212829 hasConcept C2908647359 @default.
• W2952212829 hasConcept C41008148 @default.
• W2952212829 hasConcept C61511704 @default.
• W2952212829 hasConcept C71924100 @default.
• W2952212829 hasConcept C72563966 @default.
• W2952212829 hasConcept C77088390 @default.
• W2952212829 hasConcept C98274493 @default.
• W2952212829 hasConcept C99454951 @default.
• W2952212829 hasConceptScore W2952212829C107130276 @default.
• W2952212829 hasConceptScore W2952212829C120665830 @default.
• W2952212829 hasConceptScore W2952212829C121332964 @default.
• W2952212829 hasConceptScore W2952212829C126322002 @default.
• W2952212829 hasConceptScore W2952212829C1862650 @default.
• W2952212829 hasConceptScore W2952212829C198451711 @default.
• W2952212829 hasConceptScore W2952212829C23276603 @default.
• W2952212829 hasConceptScore W2952212829C2426938 @default.
• W2952212829 hasConceptScore W2952212829C2777575956 @default.
• W2952212829 hasConceptScore W2952212829C2779338263 @default.
• W2952212829 hasConceptScore W2952212829C2779605438 @default.
• W2952212829 hasConceptScore W2952212829C2780653079 @default.
• W2952212829 hasConceptScore W2952212829C2908647359 @default.
• W2952212829 hasConceptScore W2952212829C41008148 @default.
• W2952212829 hasConceptScore W2952212829C61511704 @default.
• W2952212829 hasConceptScore W2952212829C71924100 @default.
• W2952212829 hasConceptScore W2952212829C72563966 @default.
• W2952212829 hasConceptScore W2952212829C77088390 @default.
• W2952212829 hasConceptScore W2952212829C98274493 @default.
• W2952212829 hasConceptScore W2952212829C99454951 @default.
• W2952212829 hasLocation W29522128291 @default.
• W2952212829 hasOpenAccess W2952212829 @default.
• W2952212829 hasPrimaryLocation W29522128291 @default.
• W2952212829 hasRelatedWork W2313398487 @default.
• W2952212829 hasRelatedWork W2315815725 @default.
• W2952212829 hasRelatedWork W2552108668 @default.
• W2952212829 hasRelatedWork W2754241130 @default.
• W2952212829 hasRelatedWork W2754803002 @default.
• W2952212829 hasRelatedWork W2949483997 @default.
• W2952212829 hasRelatedWork W2951669248 @default.
• W2952212829 hasRelatedWork W2952209514 @default.
• W2952212829 hasRelatedWork W2952939036 @default.
• W2952212829 hasRelatedWork W2953092261 @default.
• W2952212829 hasRelatedWork W3033114320 @default.
• W2952212829 hasRelatedWork W3033489031 @default.
• W2952212829 hasRelatedWork W3033809365 @default.
• W2952212829 hasRelatedWork W3034982030 @default.
• W2952212829 hasRelatedWork W3043571938 @default.
• W2952212829 hasRelatedWork W3105464358 @default.
• W2952212829 hasRelatedWork W3123163825 @default.

• next